Research Compound
KLOW (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg)
KLOW is a research-grade peptide blend containing BPC-157 10mg, GHK-Cu 50mg, TB-500 10mg, and KPV 10mg in a single lyophilized formulation for laboratory investigation.
Select Size
80mg
SKU: KLOW80
Batch: 202510-01-KLOW
$150.99
Ships today if ordered by 4PM EST
Est. Arrival: 09/18/2026
Volume Discounts
Qty: 1 - 4$150.99 each
Qty: 5 - 9$135.89 each(save $15.10)
Qty: 10+$120.79 each(save $30.20)
Quantity:
1
For Research Use Only. This product is intended for laboratory and scientific research purposes only. It is not a drug or dietary supplement and is not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
99%+ Purity
COA Included
Fast Shipping
USA Based
Product Details
KLOW combines four distinct peptide compounds in a single research formulation:
BPC-157 – A 15-amino acid synthetic peptide sequence (10mg)
GHK-Cu – A tripeptide-copper complex (50mg)
TB-500 – Thymosin Beta-4 (Tb4), the full 43-amino-acid peptide, sold under the research name TB-500 (10mg)
KPV – A C-terminal tripeptide fragment (10mg)
This blend is provided as a lyophilized powder for reconstitution.
Disclaimer: This compound is provided strictly for laboratory and research purposes only. It is not intended for human consumption.
Frequently Asked Questions About KLOW (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg)
Answers summarize published research and are provided for laboratory research purposes only.
KLOW (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg) is a four-peptide research blend supplied in a single lyophilized vial. It contains 10 mg of BPC-157, a 15-amino acid synthetic peptide, 50 mg of GHK-Cu, a tripeptide-copper complex, 10 mg of TB-500, which is Thymosin Beta-4, the full 43-amino acid peptide, and 10 mg of KPV, a tripeptide fragment. Biotech Compounds supplies the KLOW blend for laboratory research.
Research studies describe four separate mechanisms in the KLOW blend. Researchers have reported that BPC-157 acts on nitric oxide and growth factor signaling, that GHK-Cu delivers copper and modulates gene expression tied to remodeling, that TB-500, or Thymosin Beta-4, binds G-actin and influences cell migration, and that KPV, the C-terminal fragment of alpha-MSH, reduces NF-kB driven inflammatory signaling in cell models.
The primary research area shared by the KLOW components is tissue repair and remodeling. In animal models, researchers have reported examining BPC-157 in tendon, ligament, and gut injury, GHK-Cu in wound and skin remodeling, and TB-500 as Thymosin Beta-4 in dermal and cardiac repair models. The KLOW blend places those three repair-focused peptides together with KPV in one vial for research use.
KPV is the component that separates KLOW from the three-peptide Glow blend. In research studies, KPV has been examined in models of intestinal inflammation and skin inflammation, where researchers reported it reduced inflammatory cytokine signaling. In vitro studies have observed that KPV enters cells through the PepT1 transporter. Its inclusion gives the KLOW blend an anti-inflammatory research angle alongside the repair-focused peptides.
The evidence base for KLOW is preclinical and is built from research on each peptide separately rather than on the blend as a whole. BPC-157, GHK-Cu, Thymosin Beta-4, and KPV each have in vitro and animal model data, and Thymosin Beta-4 has been through early clinical trials that did not lead to approval. KLOW is an investigational research blend and is not an approved drug.
KLOW and Glow share the same three peptides at the same amounts, BPC-157 10 mg, GHK-Cu 50 mg, and TB-500 10 mg, where TB-500 is Thymosin Beta-4. KLOW adds a fourth peptide, KPV, at 10 mg. Researchers choose KLOW when the study design calls for the anti-inflammatory tripeptide alongside the repair peptides, and Glow when only the three-peptide combination is wanted. Biotech Compounds sells both blends as separate research products.
KLOW is supplied as a combined lyophilized powder for reconstitution. Researchers add Bacteriostatic Water slowly down the inside of the vial and swirl gently until the powder dissolves. The vial should not be shaken. Because the KLOW blend contains 80 mg of total peptide plus a copper complex, the reconstituted solution is usually a pale blue color from the GHK-Cu and may need a little more time to fully dissolve than a single-peptide vial.
Lyophilized KLOW should be kept frozen or in a cool, dry, dark place, protected from light and moisture. After reconstitution the solution should be refrigerated at 2 to 8 C and protected from light. Repeated freeze thaw cycles should be avoided. Researchers have reported that Thymosin Beta-4 and BPC-157 retain activity for extended periods when kept cold, while GHK-Cu solutions are sensitive to light, so the vial should stay covered.
Yes. KLOW from Biotech Compounds is listed at 99 percent plus purity. Each lot of the blend is tested by an independent third-party laboratory, and the Certificate of Analysis is posted on the product page. Researchers can review identity and purity data for the BPC-157, GHK-Cu, TB-500, and KPV content of the specific KLOW lot before it is used.
The product specifications for KLOW list an approximate molecular weight of 7128.4 g/mol and a molecular formula of C307H500CuN78O106S. Those values reflect the combined composition of the four peptides, with the single copper atom coming from GHK-Cu and the sulfur from the methionine in Thymosin Beta-4. The blend contains 80 mg of total peptide per vial as stated in the product name.
No. KLOW (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg) is sold by Biotech Compounds strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 years of age or older. KLOW is not a drug or a dietary supplement, has not been approved by the FDA, and is not for human or animal consumption.
You May Also Like
